Nurzat Yeltai, Dai Damao, Hu Julong, Zhang Feiyu, Lin Zaihuan, Huang Yang, Gang Liang, Ji Hang, Zhang Xiaowen
State Key Laboratory of Respiratory Disease, Department of Otolaryngology-Head and Neck Surgery, First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Department of Plastic and Cosmetic Surgery, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.
Front Oncol. 2023 Apr 25;13:1162406. doi: 10.3389/fonc.2023.1162406. eCollection 2023.
Cutaneous melanoma (CM) is an aggressive type of skin cancer. Even after standard treatment, the recurrence and malignant progression of CM were almost inevitable. The overall survival (OS) of patients with CM varied widely, making it critical for prognostic prediction. Based on the correlation between CCR6 and melanoma incidence, we aimed to investigate the prognostic role of CCR6 and its relationship with immune infiltration in CM.
We obtained RNA sequencing data from The Cancer Genome Atlas (TCGA) to analyze the CM expression. Functional enrichment analyses, immune infiltration analyses, immune checkpoint analyses, and clinicopathology analyses were performed. Univariate and multivariate Cox regression analyses were used to identify independent prognostic factors. A nomogram model had been developed. Kaplan-Meier survival analysis and log-rank test were used to estimate the relationship between OS and CCR6 expression.
CCR6 was significantly upregulated in CM. Functional enrichment analyses revealed that CCR6 was correlated with immune response. Most immune cells and immune checkpoints were positively correlated with CCR6 expression. Kaplan-Meier analyses showed that high CCR6 expression was associated with a good outcome in CM and its subtypes. Cox regression showed that CCR6 was an independent prognostic factor in patients with CM (HR = 0.550, 95% CI = 0.332-0.912, <0.05).
CCR6 is considered to be a new prognostic biomarker for patients with CM, and our study provides a potential therapeutic target for CM treatment.
皮肤黑色素瘤（CM）是一种侵袭性皮肤癌。即使经过标准治疗，CM的复发和恶性进展几乎不可避免。CM患者的总生存期（OS）差异很大，这使得预后预测至关重要。基于CCR6与黑色素瘤发病率之间的相关性，我们旨在研究CCR6在CM中的预后作用及其与免疫浸润的关系。
我们从癌症基因组图谱（TCGA）获取RNA测序数据以分析CM表达。进行了功能富集分析、免疫浸润分析、免疫检查点分析和临床病理分析。使用单因素和多因素Cox回归分析来确定独立的预后因素。建立了列线图模型。采用Kaplan-Meier生存分析和对数秩检验来评估OS与CCR6表达之间的关系。
CCR6在CM中显著上调。功能富集分析表明CCR6与免疫反应相关。大多数免疫细胞和免疫检查点与CCR6表达呈正相关。Kaplan-Meier分析表明，高CCR6表达与CM及其亚型的良好预后相关。Cox回归显示CCR6是CM患者的独立预后因素（HR = 0.550，95% CI = 0.332 - 0.912，<0.05）。
CCR6被认为是CM患者的一种新的预后生物标志物，我们的研究为CM治疗提供了一个潜在的治疗靶点。
